CV Lattes
ResearcherID
ORCID
Secretaria da Saúde (São Paulo - Estado). Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP (HCMRP). Hemocentro de Ribeirão Preto (Institutional affiliation from the last research proposal) Birthplace: Brazil
Virginia Picanço e Castro in research grants and scholarships supported by FAPESP.
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The Nucleus of Cellular Therapy - NuTeC will be founded on the union of the Regional Blood Center of Ribeirão Preto (Hemocentro RP) and Butantan. Hemocentro RP expertise in cellular therapy will be added to Butantan excellence in the development and production of health applied products to develop CAR T cell therapy. The activities to be conducted by NuTeC are aligned with the scope of th…
In recent years, enormous advances have been made in genetic engineering of effector immune cells for cancer therapy. Although chimeric antigen receptors (CARs) have been widely used to redirect autologous T cell specificity against haematological malignancies, yielding impressive clinical results, studies with CAR-modified natural killer (NK) cells are still restricted to preclinical stu…
Hemophilia is a genetic disorder linked to the X chromosome which results in deficiency or abnormality of factor VIII protein (FVIII). The replacement therapy using protein derived from human plasma or recombinant produced in hamster cell lines (CHO and / or BHK) are the only treatment options available. However, one of the largest replacement therapy problems is the formation of inhibito…
Hematological malignancies represent a significant portion among the diagnoses of neoplastic cells. Adoptive cell therapy with T cells genetically modified to express chimeric antigen receptors(CAR) has revolutionized the field, with promising and impressive results. However, there are still obstacles associated with the use of CAR-modified T cells, such as the need of autologous cells an…
Therapies using CAR cells are available via autologous processes, as T cells require high HLA compatibility and allogeneic therapies have a high chance of developing graft-versus-host disease. Allogeneic therapeutic processes (off-the-shelf) allow immediate availability of cells, reducing patient waiting time. The generation of NK-CAR cells is an alternative, due to its high cytotoxic cap…
Therapy with T-CAR cells against hematological neoplasm antigens, such as CAR-T anti CD19, has shown excellent remission rates. However, this type of CAR-T cell therapy is limited by the availability of tumor-specific surface antigens, sparing normal cells. There is a rich diversity of intracellularly expressed tumor protein antigens that current and conventional CAR-T cells are unable to…
(Only some records are available in English at this moment)
Immunotherapy with modified T cells to express chimeric antigen receptor (CAR) has been proven effective in remission of acute lymphoblastic leukemia (ALL) in children and young adults. The CAR possess an extracellular domain derived from antibody variable regions, and intracellular domains of T cell costimulation. CD19 protein has been shown to be an ideal target for therapies with CAR b…
Hematopoiesis is the process of formation of blood cellular components from the differentiation of hematopoietic stem cells (HSC). The HSCs are found in adult human bone marrow cells at a ratio of 1 in every 10^6 cells. The difficulty in obtaining these cells and determining a protocol for ex vivo expansion leads us to seek alternative sources for the production of mature blood cells. Ind…
| 1 / 1 | Ongoing research grants |
| 2 / 2 | Completed research grants |
| 4 / 4 | Ongoing scholarships in Brazil |
| 7 / 3 | Completed scholarships in Brazil |
| 1 / 0 | Completed scholarships abroad |
| 15 / 10 | All research grants and scholarships |
| Associated processes | |